Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Milton CI"'
Autor:
Samant RS; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, United Kingdom; Signalling Programme, The Babraham Institute, Cambridge, United Kingdom. Electronic address: rahul.samant@babraham.ac.uk., Batista S; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, United Kingdom., Larance M; Centre for Gene Regulation & Expression, University of Dundee, Dundee, United Kingdom., Ozer B; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, United Kingdom., Milton CI; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, United Kingdom., Bludau I; Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany., Wu E; Signalling Programme, The Babraham Institute, Cambridge, United Kingdom., Biggins L; Bioinformatics Group, The Babraham Institute, Cambridge, United Kingdom., Andrews S; Bioinformatics Group, The Babraham Institute, Cambridge, United Kingdom., Hervieu A; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, United Kingdom., Johnston HE; Signalling Programme, The Babraham Institute, Cambridge, United Kingdom., Al-Lazikhani B; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, United Kingdom; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Lamond AI; Centre for Gene Regulation & Expression, University of Dundee, Dundee, United Kingdom., Clarke PA; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, United Kingdom., Workman P; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, United Kingdom. Electronic address: paul.workman@icr.ac.uk.
Publikováno v:
Molecular & cellular proteomics : MCP [Mol Cell Proteomics] 2023 Feb; Vol. 22 (2), pp. 100485. Date of Electronic Publication: 2022 Dec 20.
Autor:
Milton CI; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, UK., Selfe J; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, UK., Aladowicz E; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, UK., Man SYK; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, UK., Bernauer C; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, UK., Missiaglia E; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, UK., Walters ZS; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, UK., Gatz SA; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, UK., Kelsey A; Department of Paediatric Histopathology, Manchester University NHS Foundation Trust, Royal Manchester Children's Hospital, UK., Generali M; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, UK., Box G; Cancer Pharmacology and Stress Response Team, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Valenti M; Cancer Pharmacology and Stress Response Team, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., de Haven-Brandon A; Cancer Pharmacology and Stress Response Team, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Galiwango D; Drug Metabolism and Pharmacokinetics Team, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Hayes A; Drug Metabolism and Pharmacokinetics Team, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Clarke M; Glioma Team, Division of Molecular Pathology, The Institute of Cancer Research, London, UK., Izquierdo E; Glioma Team, Division of Molecular Pathology, The Institute of Cancer Research, London, UK., Gonzalez De Castro D; Molecular Haematology, Division of Molecular Pathology, The Institute of Cancer Research, London, UK., Raynaud FI; Drug Metabolism and Pharmacokinetics Team, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Kirkin V; Cancer Pharmacology and Stress Response Team, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Shipley JM; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, UK.
Publikováno v:
Molecular oncology [Mol Oncol] 2022 Mar; Vol. 16 (6), pp. 1272-1289. Date of Electronic Publication: 2021 Dec 18.